Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2014 (2014), Article ID 142154, 10 pages
http://dx.doi.org/10.1155/2014/142154
Research Article

Chronic Treatment with Ang-(1-7) Reverses Abnormal Reactivity in the Corpus Cavernosum and Normalizes Diabetes-Induced Changes in the Protein Levels of ACE, ACE2, ROCK1, ROCK2 and Omega-Hydroxylase in a Rat Model of Type 1 Diabetes

1Department of Pharmacology and Toxicology, Faculty of Medicine, Kuwait University, P.O. Box 24923, 13110 Safat, Kuwait
2Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Kuwait University, P.O. Box 24923, 13110 Safat, Kuwait

Received 29 May 2014; Revised 31 July 2014; Accepted 1 August 2014; Published 16 September 2014

Academic Editor: Mark A. Yorek

Copyright © 2014 Mariam H. M. Yousif et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Gur, T. C. Peak, P. J. Kadowitz, S. C. Sikka, and W. J. G. Hellstrom, “Review of erectile dysfunction in diabetic animal models,” Current Diabetes Reviews, vol. 10, no. 1, pp. 61–73, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Zheng, X. Liu, and K. P. Patel, “Centrally mediated erectile dysfunction in rats with type 1 diabetes: role of angiotensin II and superoxide,” Journal of Sexual Medicine, vol. 10, no. 9, pp. 2165–2176, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. K.-E. Andersson, “Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction,” Pharmacological Reviews, vol. 63, no. 4, pp. 811–859, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. V. S. Thorve, A. D. Kshirsagar, N. S. Vyawahare, V. S. Joshi, K. G. Ingale, and R. J. Mohite, “Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management,” Journal of Diabetes and its Complications, vol. 25, no. 2, pp. 129–136, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Scully, “Diabetes in numbers,” Nature, vol. 485, pp. S2–S3, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. D. R. Whiting, L. Guariguata, C. Weil, and J. Shaw, “IDF diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030,” Diabetes Research and Clinical Practice, vol. 94, no. 3, pp. 311–321, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. R. A. Fraga-Silva, F. Montecucco, F. Mach, R. A. S. Santos, and N. Stergiopulos, “Pathophysiological role of the renin-angiotensin system on erectile dysfunction,” European Journal of Clinical Investigation, vol. 43, no. 9, pp. 978–985, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. I. A. Aytaç, J. B. McKinlay, and R. J. Krane, “The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences,” BJU International, vol. 84, no. 1, pp. 50–56, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. L. S. Malavige and J. C. Levy, “Erectile dysfunction in diabetes mellitus,” Journal of Sexual Medicine, vol. 6, no. 5, pp. 1232–1247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Price and G. Hackett, “Management of erectile dysfunction in diabetes: an update for 2008,” Current Diabetes Reports, vol. 8, no. 6, pp. 437–443, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Decaluwé, B. Pauwels, C. Boydens, and J. van de Voorde, “Treatment of erectile dysfunction: new targets and strategies from recent research,” Pharmacology Biochemistry and Behavior, vol. 121, pp. 146–157, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. R. A. Fraga-Silva, F. P. Costa-Fraga, S. Q. Savergnini et al., “An oral formulation of Angiotensin-(1-7) reverses corpus cavernosum damages induced by Hypercholesterolemia,” Journal of Sexual Medicine, vol. 10, no. 10, pp. 2430–2442, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Kilarkaje, M. H. M. Yousif, A. Z. El-Hashim, B. Makki, S. Akhtar, and I. F. Benter, “Role of angiotensin II and angiotensin-(1-7) in diabetes-induced oxidative DNA damage in the corpus cavernosum,” Fertility and Sterility, vol. 100, no. 1, pp. 226–233, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. M. H. Yousif, E. O. Kehinde, and I. F. Benter, “Different responses to angiotensin-(1–7) in young, aged and diabetic rabbit corpus cavernosum,” Pharmacological Research, vol. 56, no. 3, pp. 209–216, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. L.-M. Jin, “Angiotensin II signaling and its implication in erectile dysfunction,” Journal of Sexual Medicine, vol. 6, no. 3, pp. 302–310, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. V. B. Patel, N. Parajuli, and G. Y. Oudit, “Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications,” Clinical Science, vol. 126, no. 7, pp. 471–482, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. R. A. S. Santos, A. J. Ferreira, T. Verano-Braga, and M. Bader, “Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system,” Journal of Endocrinology, vol. 216, no. 2, pp. R1–R17, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. I. F. Benter, M. H. M. Yousif, C. Cojocel, M. Al-Maghrebi, and D. I. Diz, “Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction,” American Journal of Physiology: Heart and Circulatory Physiology, vol. 292, no. 1, pp. H666–H672, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. H. M. Yousif and I. F. Benter, “Role of cytochrome P450 metabolites of arachidonic acid in regulation of corporal smooth muscle tone in diabetic and older rats,” Vascular Pharmacology, vol. 47, no. 5-6, pp. 281–287, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. H. M. Yousif, I. F. Benter, K. M. J. Dunn, A. J. Dahly-Vernon, S. Akhtar, and R. J. Roman, “Role of 20-hydroxyeicosatetraenoic acid in altering vascular reactivity in diabetes,” Autonomic and Autacoid Pharmacology, vol. 29, no. 1-2, pp. 1–12, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. A. C. Da Costa Gonçalves, R. Leite, R. A. Fraga-Silva et al., “Evidence that the vasodilator angiotensin-(1-7)-Mas axis plays an important role in erectile function,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 293, no. 4, pp. H2588–H2596, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Shi and L. Wei, “Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil,” Journal of Cardiovascular Pharmacology, vol. 62, no. 4, pp. 341–354, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. T. J. Bivalacqua, H. C. Champion, M. F. Usta et al., “RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 24, pp. 9121–9126, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. A. M. Alsaad, B. N. Zordoky, M. M. Tse, and A. O. El-Kadi, “Role of cytochrome P450-mediated arachidonic acid metabolites in the pathogenesis of cardiac hypertrophy,” Drug Metabolism Reviews, vol. 45, no. 2, pp. 173–195, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Fan, C.-W. Sun, K. G. Maier et al., “20-Hydroxyeicosatetraenoic acid contributes to the inhibition of K+ channel activity and vasoconstrictor response to angiotensin II in rat renal microvessels,” PLoS ONE, vol. 8, no. 12, Article ID e82482, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. D. L. Kroetz and F. Xu, “Regulation and inhibition of arachidonic acid ω-hydroxylases and 20-HETE formation,” Annual Review of Pharmacology and Toxicology, vol. 45, pp. 413–438, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. J. F. Giani, M. M. Gironacci, M. C. Muñoz, D. Turyn, and F. P. Dominici, “Angiotensin-(1-7) has a dual role on growth-promoting signalling pathways in rat heart in vivo by stimulating STAT3 and STAT5a/b phosphorylation and inhibiting angiotensin II-stimulated ERK1/2 and Rho kinase activity,” Experimental Physiology, vol. 93, no. 5, pp. 570–578, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. M. M. Muthalif, I. F. Benter, M. R. Uddin, J. L. Harper, and K. U. Malik, “Signal transduction mechanisms involved in angiotensin-(1-7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 284, no. 1, pp. 388–398, 1998. View at Google Scholar · View at Scopus
  29. I. F. Benter, M. H. M. Yousif, F. M. Al-Saleh, R. Raghupathy, M. C. Chappell, and D. I. Diz, “Angiotensin-(1-7) blockade attenuates captopril- or hydralazine-induced cardiovascular protection in spontaneously hypertensive rats treated with NG-nitro-l-arginine methyl ester,” Journal of Cardiovascular Pharmacology, vol. 57, no. 5, pp. 559–567, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Z. El-Hashim, W. M. Renno, R. Raghupathy, H. T. Abduo, S. Akhtar, and I. F. Benter, “Angiotensin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2- and NF-κB-dependent pathways,” British Journal of Pharmacology, vol. 166, no. 6, pp. 1964–1976, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. W. M. Renno, A. G. Al-Banaw, P. George, A. A. Abu-Ghefreh, S. Akhtar, and I. F. Benter, “Angiotensin-(1-7) via the mas receptor alleviates the diabetes-induced decrease in GFAP and GAP-43 immunoreactivity with concomitant reduction in the COX-2 in hippocampal formation: an immunohistochemical study,” Cellular and Molecular Neurobiology, vol. 32, no. 8, pp. 1323–1336, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Akhtar, M. H. Yousif, G. S. Dhaunsi, B. Chandrasekhar, O. Al-Farsi, and I. F. Benter, “Angiotensin-(1–7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway,” British Journal of Pharmacology, vol. 165, no. 5, pp. 1390–1400, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. M. H. M. Yousif, G. S. Dhaunsi, B. M. Makki, B. A. Qabazard, S. Akhtar, and I. F. Benter, “Characterization of Angiotensin-(1-7) effects on the cardiovascular system in an experimental model of Type-1 diabetes,” Pharmacological Research, vol. 66, no. 3, pp. 269–275, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Akhtar, M. H. M. Yousif, G. S. Dhaunsi et al., “Activation of ErbB2 and downstream signalling via Rho kinases and ERK1/2 contributes to diabetes-induced vascular dysfunction,” PLoS ONE, vol. 8, no. 6, Article ID e67813, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Bader, “ACE2, angiotensin-(1-7), and Mas: The other side of the coin,” Pflugers Archiv European Journal of Physiology, vol. 465, no. 1, pp. 79–85, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Chen, S. X. Li, L. S. Yao, R. Wang, and Y. T. Dai, “Valsartan treatment reverses erectile dysfunction in diabetic rats,” International Journal of Impotence Research, vol. 19, no. 4, pp. 366–370, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. M. T. Abdel Aziz, M. F. El Asmer, T. Mostafa et al., “Effects of Losartan, HO-1 Inducers or HO-1 inhibitors on erectile signaling in diabetic rats,” Journal of Sexual Medicine, vol. 6, no. 12, pp. 3254–3264, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. I. Kifor, G. H. Williams, M. A. Vickers, M. P. Sullivan, P. Jodbert, and R. G. Dluhy, “Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum,” Journal of Urology, vol. 157, no. 5, pp. 1920–1925, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Iusuf, R. H. Henning, W. H. van Gilst, and A. J. M. Roks, “Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives,” European Journal of Pharmacology, vol. 585, no. 2-3, pp. 303–312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. Z. Ying, L. Jin, T. Palmer, and R. C. Webb, “Angiotensin II up-regulates the leukemia-associated Rho guanine nucleotide exchange factor (RhoGEF), a regulator of G protein signaling domain-containing RhoGEF, in vascular smooth muscle cells,” Molecular Pharmacology, vol. 69, no. 3, pp. 932–940, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. A. V. Schofield and O. Bernard, “Rho-associated coiled-coil kinase (ROCK) signaling and disease,” Critical Reviews in Biochemistry and Molecular Biology, vol. 48, no. 4, pp. 301–316, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. J. L. Hannan, M. Albersen, O. Kutlu et al., “Inhibition of Rho-kinase improves erectile function, increases nitric oxide signaling and decreases penile apoptosis in a rat model of cavernous nerve injury,” Journal of Urology, vol. 189, no. 3, pp. 1155–1161, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. M. C. Cho, K. Park, J. S. Chai, S. H. Lee, S. W. Kim, and J. S. Paick, “Involvement of sphingosine-1-Phosphate/RhoA/Rho-Kinase signaling pathway in corporal fibrosis following cavernous nerve injury in male rats,” Journal of Sexual Medicine, vol. 8, no. 3, pp. 712–721, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. H. A. Toque, K. P. Nunes, L. Yao et al., “Activated rho kinase mediates diabetes-induced elevation of vascular arginase activation and contributes to impaired corpora cavernosa relaxation: possible involvement of p38 MAPK activation,” Journal of Sexual Medicine, vol. 10, no. 6, pp. 1502–1515, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. M. H. M. Yousif, I. F. Benter, and R. J. Roman, “Cytochrome P450 metabolites of arachidonic acid play a role in the enhanced cardiac dysfunction in diabetic rats following ischaemic reperfusion injury,” Autonomic and Autacoid Pharmacology, vol. 29, no. 1-2, pp. 33–41, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. M. H. M. Yousif and I. F. Benter, “Role of 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids in the regulation of vascular function in a model of hypertension and endothelial dysfunction,” Pharmacology, vol. 86, no. 3, pp. 149–156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. I. F. Benter, M. H. Yousif, H. Canatan, and S. Akhtar, “Inhibition of Ca2+/calmodulin -dependent protein kinase II, RAS- GTPase and 20-hydroxyeicosatetraenoic acid attenuates the development of diabetes-induced vascular dysfunction in the rat carotid artery,” Pharmacological Research, vol. 52, no. 3, pp. 252–257, 2005. View at Google Scholar
  48. I. F. Benter, I. Francis, C. Cojocel, J. S. Juggi, M. H. M. Yousif, and H. Canatan, “Contribution of cytochrome P450 metabolites of arachidonic acid to hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME,” Autonomic and Autacoid Pharmacology, vol. 25, no. 4, pp. 143–154, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. A. C. da Costa Gonçalves, R. A. Fraga-Silva, R. Leite, and R. A. S. Santos, “AVE 0991, a non-peptide Mas-receptor agonist, facilitates penile erection,” Experimental Physiology, vol. 98, no. 3, pp. 850–855, 2013. View at Publisher · View at Google Scholar · View at Scopus